Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2024 07:00 ET | Source: Olema Oncology

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission...
December 17, 2020 08:00 ET | Source: Biotheranostics, Inc.

Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients

San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage...
December 08, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020

San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
December 03, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology

San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially...
October 29, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors

San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast...
May 15, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial

San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...
February 24, 2020 08:00 ET | Source: Biotheranostics, Inc.

Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology

San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
March 05, 2019 09:00 ET | Source: Biotheranostics, Inc.

Breast Cancer Index® Receives Expanded Medicare Coverage Under a New Local Coverage Determination

San Diego, CA, March 05, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces its Breast Cancer Index (BCI) test has been issued a new Medicare Local Coverage Determination [(LCD) L37822] by...
May 23, 2016 16:06 ET | Source: KantarHealth

Younger Women Are More Likely to Be Non-Adherent to Oral Breast Cancer Therapies, Kantar Health Says

NEW YORK CITY, N.Y., May 23, 2016 (GLOBE NEWSWIRE) -- Women who are younger, have lower income and are ethnically non-white are more likely to be non-adherent to oral endocrine therapy (ET) for breast...